Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer

Inclusion Criteria: 1. Age of equal or older than 18 years and not over 75 years with a life expectancy of at least 12 weeks; 2. Karnofsky performance status (KPS) of ≥70; 3. Histologically or cytologically confirmed HCC; 4. BCLC stage B, solitary lesion (bigger than 5 cm in diameter) with tumor burden less than 50% of total liver volume; 5. Liver function of Child-Pugh A; 6. Technically unresectable, medically inoperable, or surgery declined by the patient; 7. Normal renal function and adequate bone marrow reservation; 8. Signed informed consent must be obtained prior to any study specific procedure. Exclusion Criteria: 1. Presence of intrahepatic and/or extrahepatic metastases 2. Previous received systemic therapy for liver cancer; 3. History of radiotherapy to the liver; 4. Indistinct tumor boundary on CT/MRI images; 5. Previous or concurrent malignancies, with the exception of adequately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix or superficial bladder tumors \[Ta, Tis and T1\]; 6. History of cardiac disease: congestive heart failure \> NYHA class 2, active CAD, cardiac arrythmias requiring anti-arrhythmic therapy or uncontrolled hypertension within the last 12 months; 7. Concurrent uncontrolled medical conditions; 8. Pregnancy or breast feeding; 9. Investigational drug therapy outside of this trial during or within 4 weeks of study entry; 10. Psychiatric or medical unstable conditions that compromise the patient's ability to give informed consent.